Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
140 hedge funds and large institutions have $1.23B invested in Alder Biopharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 62 increasing their positions, 35 reducing their positions, and 19 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 35
74% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 19
10% more funds holding
Funds holding: 127 → 140 (+13)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
28% less capital invested
Capital invested by funds: $1.69B → $1.23B (-$469M)
73% less call options, than puts
Call options by funds: $2.4M | Put options by funds: $8.78M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$144M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.3M |
| 3 |
SAM
Senzar Asset Management
New York
|
+$23.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.7M |
| 5 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$103M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$16.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$14M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$9.64M |
| 5 |
PC
PointState Capital
New York
|
-$7.95M |
ALDR Hedge Fund Activity: Q3 2015 in Review
140 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q3 2015, worth a combined $1.23B — down 28% from $1.69B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ALDR positions and 19 closed out — a net gain of 14 holders — while 62 added to existing stakes and 35 trimmed.
The largest buyer was Janus Henderson Investors US, adding an estimated $144M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $103M sold.
- 140 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q3 2015, up from 127 in Q2 2015.
- Funds reported $1.23B of Alder Biopharmaceuticals stock for Q3 2015, down 28% quarter-over-quarter.
- 33 funds opened new Alder Biopharmaceuticals positions in Q3 2015 and 19 closed out, a net change of +14 holders.
- The largest Alder Biopharmaceuticals buyer in Q3 2015 was Janus Henderson Investors US, an estimated $144M added.
- The largest Alder Biopharmaceuticals seller in Q3 2015 was Novo Holdings A/S, an estimated $103M sold.
Based on aggregated 13F filings for Q3 2015.